metastases), and matched normal tissue. Whole exome (WES) and RNA sequencing of tumors was conducted. Patient-derived xenograft (PDX) models were generated from a subset of patients, and the engrafted tumors were analyzed.
INTRODUCTION AND OBJECTIVES: Level 1 evidence shows that mTOR inhibition is associated with clinically significant reductions in tumor size in angiomyolipomas (AMLs) associated with Tuberous Sclerosis. We conducted a phase II, multi-center trial assessing the effectiveness and tolerability of everolimus (EVE) for sporadic AMLs and report the tolerability and adverse effect (AE) data here.
METHODS: We conducted a prospective, phase II clinical trial in patients presenting with >3cm sporadic AMLs who were candidates for surgical or percutaneous intervention. Response was defined as !25% volumetric reduction of the AML. Baseline, 4-and 6-month volumetric analysis was performed by dynamic contrast-enhanced MRI (DCE-MRI). Patients received EVE 10mg for 4 28-day cycles, at which point EVE was discontinued in those with !25% volumetric reduction. Those with !25% volumetric reduction received two additional cycles of EVE. Dose reductions and interruptions were allowed to 5 mg QOD. AEs and patient decisions to withdraw from the trial were categorized. Conservative stopping rules were established for toxicity.
RESULTS: We enrolled 20 patients (median age [ 68) with 21 sporadic AMLs. 11/20 (55%) patients completed 4 cycles of EVE, and 7/ 20 (35%) completed 6 cycles. Efficacy was demonstrated, with 10/16 (62.5%) patients exhibiting !25% reduction in tumor volume at 4 months and 8/12 (66.6%) patients exhibiting !25% reduction in tumor volume at 6 months. 4/20 (20%) patients were withdrawn due to predefined toxicities, including grade 3 mucositis, grade 1 pneumonitis, grade 2 pneumonitis, and grade 2 hyperglycemia. Dose reductions were required in 6/20 (30%) patients. 2 (10%) patients required two dose reductions, and 4 (20%) patients required a single dose reduction. 19/20 (95%) of patients experienced at least one grade 2 AE during the trial. 5/20 (25%) patients had grade 3 toxicities (oral mucositis in 3 patients, hyperglycemia in 1 patient, and UTI in 1 patient) which resolved upon discontinuation or dose reduction of EVE. Of the 8/20 (40%) patients who withdrew due to personal preference, a mean of 13.75 AEs were experienced, mainly grade 1 and 2. The most common AEs during the trial included oral mucositis (70%), increased ALT (55%), hyperlipidemia (55%), increased AST (50%), anemia (50%), hyperglycemia (40%), and fatigue (40%).
CONCLUSIONS: EVE was associated with a high rate of treatment termination due to patient preference or protocol-defined AEs. Patients appear to be less willing to tolerate the side-effect profile of EVE for benign lesions such as AMLs as they be might for metastatic renal cell carcinoma.
Source of Funding: Novartis Pharmaceuticals

PD03-12 EXPRESSION OF SETD2 COMBINED WITH PBRM1 AS PROGNOSTIC PREDICTOR IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA RECEIVING TYROSINE KINASE INHIBITOR
Wen Cai*, Jiwei Huang, Zaoyu Wang, Yichu Yuan, Wen Kong, Jin Zhang, Yonghui Chen, Qiang Liu, Wei Xue, Yiran Huang, shanghai, China, People's Republic of INTRODUCTION AND OBJECTIVES: PBRM1, BAP1 and SETD2 mutations are both located on chromosome 3p and common in clear cell renal cell carcinoma(ccRCC). The purpose of this work was to detect the influence of expression of PBRM1, BAP1 and SETD2 before treatment of Tyrosine Kinase Inhibitor on the prognosis of patients with metastatic renal cell carcinoma(mRCC).
METHODS: We identified 113 mRCC patients who received first-line therapy of sunitinib or sorafenib between January 2006 to December 2016 in Renji Hospital affiliated to Shanghai Jiao Tong University school of medicine. In this retrospective single-center research, PBRM1, BAP1 and SETD2 expression was assessed by immunohistochemistry, the Kaplan-Meier method was used to estimate the progression free survival (PFS) and overall survival (OS), log-rank test was used to compare the survival outcomes between patients with low and high SETD2, PBRM1 and BAP1 expression level, and cox proportional hazard regression model was used to estimate the prognostic value. Prognostic accuracy was determined using Harrell concordance index and ROC analysis.
RESULTS: Patients with low SETD2 and PBRM1 expression level had significantly shorter median PFS (11 vs 20 months, P [ 0.021; 8 vs 16 months, P [ 0.041) and OS (23 vs 35 months, P [ 0.019; 16 vs 29 months, P [ 0.004) than those with high expression level, respectively. Both low expression of PBRM1 and SETD2 showed worst prognostic. Multivariate analysis showed that SETD2 and PBRM1
